GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
IPO Year: 2014
Exchange: NASDAQ
Website: glycomimetics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/26/2024 | Buy → Hold | TD Cowen | |
12/22/2023 | $12.00 | Overweight | CapitalOne |
11/12/2021 | $3.00 → $4.00 | Hold → Buy | Jefferies |
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
3 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
4 - GLYCOMIMETICS INC (0001253689) (Issuer)
10-Q - GLYCOMIMETICS INC (0001253689) (Filer)
8-K - GLYCOMIMETICS INC (0001253689) (Filer)
8-K - GLYCOMIMETICS INC (0001253689) (Filer)
8-K - GLYCOMIMETICS INC (0001253689) (Filer)
8-K - GLYCOMIMETICS INC (0001253689) (Filer)
10-Q - GLYCOMIMETICS INC (0001253689) (Filer)
8-K - GLYCOMIMETICS INC (0001253689) (Filer)
8-K - GLYCOMIMETICS INC (0001253689) (Filer)
ARS - GLYCOMIMETICS INC (0001253689) (Filer)
DEF 14A - GLYCOMIMETICS INC (0001253689) (Filer)
TD Cowen downgraded GlycoMimetics from Buy to Hold
CapitalOne initiated coverage of GlycoMimetics with a rating of Overweight and set a new price target of $12.00
Jefferies upgraded GlycoMimetics from Hold to Buy and set a new price target of $4.00 from $3.00 previously
HC Wainwright resumed coverage of GlycoMimetics with a rating of Buy
SC 13G/A - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13G/A - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13D/A - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13D/A - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13D/A - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13G/A - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13G/A - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13D/A - GLYCOMIMETICS INC (0001253689) (Subject)
SC 13G/A - GLYCOMIMETICS INC (0001253689) (Subject)
Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di
After meeting with the U.S. Food and Drug Administration (FDA), it has been determined that the regulatory path forward for uproleselan in relapsed and refractory (R/R) Acute Myeloid Leukemia (AML) would require an additional clinical trial The Company will conduct a strategic review of the business seeking to maximize shareholder value, including the evaluation of potential business development opportunities for uproleselan and GMI-1687 to ensure their continued advancement The Company is advancing discussions with the National Cancer Institute (NCI) and Alliance for Clinical Trials in Oncology for the ongoing Phase 2/3 study of uproleselan in newly diagnosed AML patients The Com
Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3
GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company's pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML). The event will feature the study's principal investigator Daniel DeAngelo, M.D., Ph.D., Professor of Medicine, Harvard Medical School, and Chief of the Division of Leukemia, Dana-Farber Cancer Institute, who will discuss results from the pivotal Phase 3 study of up
Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing Conference call and webcast to be hosted today, May 6, 2024, at 8:30 a.m. ET. GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company
GlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based the
Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024 New Drug Application (NDA) for uproleselan to be submitted to the U.S. Food and Drug Administration (FDA) by end of 2024 if outcome of R/R AML pivotal study is positive Phase 1a study of GMI-1687, a highly potent E-selectin antagonist with an initial focus on sickle cell disease (SCD), met its primary and secondary endpoints The company has entered into a research collaboration for GMI-1687 with the ASH Research Collaborative (ASH RC), a non-profit organization established by the American Society of Hematology (ASH) Conference call and we
GlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing gly
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET. A live webcast of the panel presentation will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations. An archived recording will be available for 30 days following the event. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The Company's science is based on an
GlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on February 6, 2024 of a non-qualified stock option award to purchase an aggregate of 130,000 shares of the Company's common stock to Shantha Tyavanagimatt, Ph.D., the Company's new Senior Vice President, Technical Operations. The award was granted as an inducement equity award outside of the Company's Amended and Restated 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4) and was made as an inducement material to the acceptance of employment with the Company by the new employee. The award was comprised of an opt
First in human trial evaluating highly potent E-selectin antagonist, GMI-1687, met its primary and secondary endpoints with no dose-limiting toxicities or safety signals Single ascending dose study confirmed that subcutaneous dosing generated linear pharmacokinetics and achieved target plasma concentrations across all dosing levels GMI-1687 is being developed as a potential patient-controlled point-of-care treatment for inflammatory diseases, with initial focus on sickle cell disease (SCD) Data analysis is ongoing, with full study results to be presented at an upcoming medical meeting GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and
GlycoMimetics, Inc. (NASDAQ:GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as w
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. "Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial product launches throughout his career. As we continue to move uproleselan forward, Deepak's breadth of experience and leadership is a valuable addition to GlycoMimetics," commented Harout Semerjian, GlycoMimetics' Chief Executive Officer. Dr. Tiwari joins the Company from Rafael Pharmaceuticals where he was Vice President and Head of CMC Operations working on development of devimistat in multiple indications including p
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Bruce Johnson has joined its executive leadership team as Senior Vice President and Chief Commercial Officer. "Bruce brings to GlycoMimetics a wealth of oncology / hematology expertise particularly in leading commercial and development activities across multiple launches. He shepherded two AML drugs, Midostaurin and Venetoclax, through late-stage development and approval, uniquely qualifying him to lead the commercialization efforts of our lead asset, uproleselan, should the results of our ongoing Phase 3 registrational AML trial prove positive. His near-term focus will be to develop a commercialization strategy for uproleselan, accele
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs. Dr. DeLuca is a veteran regulatory expert who has previously led the strategy-formation and execution of multiple global NDA submissions and product registrations. Most recently she was the head of regulatory affairs at Nuvation Bio and a member of its executive leadership team. "Lisa is a seasoned executive who brings to GlycoMimetics significant expertise in regulatory strategy and agency interactions. She has successfully led programs requiring interface with both the FDA and international authorities. Most notably, while at Celator P
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the appointment of Mary Mei Chen, M.D., Ph.D. to the position of Vice President of Clinical Development, effective immediately. In this role, Dr. Chen will lead the clinical development of Actinium's CD33 program including the Actimab-A plus CLAG-M and Actimab-A plus venetoclax combination trials in relapsed and refractory Acute Myeloid Leukemia ("R/R AML"). Dr. Chen joins Actinium from GlycoMimetics, where she played a leading role in multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301). In addition to work
Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3
Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing Conference call and webcast to be hosted today, May 6, 2024, at 8:30 a.m. ET. GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company
GlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based the
Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024 New Drug Application (NDA) for uproleselan to be submitted to the U.S. Food and Drug Administration (FDA) by end of 2024 if outcome of R/R AML pivotal study is positive Phase 1a study of GMI-1687, a highly potent E-selectin antagonist with an initial focus on sickle cell disease (SCD), met its primary and secondary endpoints The company has entered into a research collaboration for GMI-1687 with the ASH Research Collaborative (ASH RC), a non-profit organization established by the American Society of Hematology (ASH) Conference call and we
GlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing gly
Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) on track to be reported by end of Q2 2024 NDA filing for uproleselan anticipated by end of 2024 pending outcome of R/R AML pivotal study Initial results for GMI-1687 Phase 1a study expected by end of Q1 2024 with initial focus to develop highly potent E-selectin antagonist as point-of-care treatment in sickle cell disease Updated independent clinical data exploring potential of uproleselan in difficult to treat subtype of AML to be presented at the American Society of Hematology (ASH) meeting in December Conference call and webcast today at 8:30 a.m. ET GlycoMi
GlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based
Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) expected by end of Q2 2024 after addition of time-based analysis option U.S. Food and Drug Administration (FDA) agrees to initial Pediatric Study Plan (iPSP) for uproleselan, and National Cancer Institute (NCI) agrees to sponsor pediatric Phase 1/2 study in acute AML First pediatric patient dosed in separate investigator-initiated Phase 1/2 study of uproleselan combined with pre-stem cell transplant conditioning regimen for chemotherapy-resistant AML Clinical pipeline expanding with planned initiation of first-in-human Phase 1a study for GMI-1687 in Q3 2023 Confer
GlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, August 2, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-bas
Pivotal Phase 3 study of uproleselan combined with cytarabine-based chemotherapy in relapsed/refractory (R/R) acute myeloid leukemia (AML) continues to be projected to reach final survival event trigger within first half of 2024 Cash and cash equivalents expected to fund current operations into late 4th quarter of 2024 Conference call and webcast today at 8:30 a.m. ET GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the first quarter ended March 31, 2023. Cash and cash equivalents as of March 31, 2023 we
- SEC Filing
GlycoMimetics, Inc. (NASDAQ:GLYC) stock is moving higher Monday after its chief medical officer disclosed the purchase of company stock. The Details: On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305,000 shares of the company. Rock purchased the shares at an average price of 26 cents. How To Buy GlycoMimetics Stock An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like GlycoMimetics‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quar
- SEC Filing
The Dow Jones index closed higher by around 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Vaxart The Trade: Vaxart, Inc. (NASDAQ:VXRT) Director W. Mark Watson bought a total of 20,000 shares at an average price of $0.68. To acquire these shares, it cost around $13,578. What's Happening: Vaxart announced Monday that proceeds from
Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di
HC Wainwright & Co. analyst Edward White reiterates GlycoMimetics (NASDAQ:GLYC) with a Neutral.